Standout Papers

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive pati... 2016 2026 2019 2022 419
  1. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 (2016)
    Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases

Immediate Impact

1 from Science/Nature 62 standout
Sub-graph 1 of 20

Citing Papers

Electrospun fiber‐based immune engineering in regenerative medicine
2024 Standout
Cell-to-cell and organ-to-organ crosstalk in the pathogenesis of alcohol-associated liver disease
2024 Standout
2 intermediate papers

Works of Catherine L Shuler being referenced

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
2016 Standout

Author Peers

Author Last Decade Papers Cites
Catherine L Shuler 540 639 355 22 924
M Bala 571 467 223 25 1.0k
K. Shah 361 558 176 25 893
Yin You 324 953 210 33 1.1k
Erica D. Dommasch 226 622 91 28 955
Anders Gülfe 817 379 279 20 1.1k
M. Hooper 356 302 92 14 789
Franz Woltering 438 443 302 28 888
E Rødevand 838 458 337 29 1.0k
Avani Joshi 300 387 77 33 895
Jacqueline B. Palmer 509 444 291 27 750

All Works

Loading papers...

Rankless by CCL
2026